Clinical trials: Glaucoma Therapy
- Condition Glaucoma Therapy
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Glaucoma, Open-Angle, Ocular Hypertension
A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
This study will evaluate 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension.
- Trial name
- LOTUSDI (NCT02020512)
- Testing
- 0.03% Bimatoprost
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Allergan
Non-infectious Anterior Uveitis, Uveitic Glaucoma
TRS4Vision - A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma
The primary objective of this study is to evaluate the efficacy and safety of TRS01 eye drops compared to active comparator in subjects with active non-infectious anterior uveitis with or without uveitic glaucoma
- Trial name
- NCT05042609
- Testing
- TRS01, FDA approved steroid eye drop (masked)
- Where
- 30 sites in United States, France and 1 more
- Volunteers
- 142 people
- Sponsor
- Tarsier Pharma
Compliance
Compliance With Once Daily Glaucoma Medication
A study to examine patient compliance with once daily glaucoma medication
- Trial name
- NCT00333463
- Testing
- Intervention
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Alcon Research
Open-angle Glaucoma (OAG), Ocular Hypertension (OHT)
Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients
Qlaris Phase 2 clinical study investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in combination with latanoprost in open-angle glaucoma (OAG) and/or ocular hypertension (OHT) patients.
- Conditions
- Open-angle Glaucoma (OAG), Ocular Hypertension (OHT), Glaucoma
- Trial name
- NCT06249152
- Testing
- QLS-111, 0.015%, QLS-111, 0.030%, QLS-111, 0.075%
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Qlaris Bio, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
An observational study comparing changing from an IOP-lowering treatment to a bimatoprost-containing IOP treatment in primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
- Trial name
- NCT01646151
- Testing
- Bimatoprost
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 2,580 people
- Sponsor
- Allergan
Glaucoma, Ocular Hypertension
Long-Term Non-Interventional Latanoprost Study
This is a non-interventional, prospective, longitudinal cohort study. A total of 150 pediatric subjects with glaucoma or elevated intraocular pressure, including 75 latanoprost-treated subjects and 75 non-topical prostaglandin…
- Trial name
- LYNX (NCT01265719)
- Testing
- No intervention other than routine medical care
- Where
- 29 sites in Belgium, Colombia and 12 more
- Volunteers
- 175 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.